A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Revolution Medicines, Inc.
Inhibrx Biosciences, Inc
Vanderbilt-Ingram Cancer Center
Eisai Inc.
Regeneron Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of California, Davis
University of California, Davis
West China Hospital
AbbVie
University of California, Davis
Eli Lilly and Company